Search - tctmd.com

Displaying 281 - 300 of 722

Sort: Relevancy | Date

Presentation TCT 2018

Sensing Renal Nerve Activity Before, During, and After Denervation: SyMap

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Jie Wang

September 24, 2018

Presentation TCT 2018

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Robert S. Schwartz

September 24, 2018

Presentation TCT 2018

Predicting Responders vs Non-Responders How to Solve the Unmet Need?

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Justin E. Davies

September 24, 2018

Presentation TCT 2018

Who are the Ideal Candidates for Renal Denervation?

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Andrew Sharp

September 24, 2018

Presentation TCT 2018

Clinical Trials All Look Positive: Is Renal Denervation Ready for Clinical Practice Now?

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Chandan Devireddy

September 24, 2018

Presentation TCT 2018

Alcohol-Mediated Renal Denervation Current Status and US Pivotal Trial Plans

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh

September 24, 2018

Presentation TCT 2018

Results and Update From the Vessix RE-INFORCE Program

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Martin B. Leon

September 24, 2018

Presentation TCT 2018

Results and Update From the Paradise Hypertension Program (OFF-MED and ON-MED Studies)

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

Results and Update From the SPYRAL Hypertension Program (OFF-MED and ON-MED Trials)

Presenter: Felix Mahfoud, Krishna J. Rocha-Singh, David E. Kandzari

September 24, 2018

Presentation TCT 2018

Device Therapy Offers a Viable Alternative to Medical Therapy, and Should Be Considered as a Reasonable Alternative!

Presenter: Joost Daemen

September 24, 2018

Presentation TCT 2018

Drugs Work and Should Always Be Used as First-Line Therapy!

Presenter: Melvin D. Lobo

September 24, 2018

Presentation TCT 2018

Potential Interventions for Hypertensive Patients With HFpEF

Presenter: Mark C. Bates, Bernard J. Gersh, Franz X. Kleber

September 24, 2018

Presentation TCT 2018

Uncontrolled Hypertension or Non-Compliant Patient? Assessment, Scope of the Problem, and Implications

Presenter: Vasilios Papademetriou, Paul A. Sobotka, C. Venkata S. Ram

September 24, 2018

Presentation TCT 2018

Have the New U.S. Hypertension Guidelines and Treatment Targets Meaningfully Changed Care Pathways and Practice?

Presenter: Vasilios Papademetriou, Paul A. Sobotka

September 24, 2018

Presentation TCT 2018

2018 European Guidelines and Perspectives on Hypertension

Presenter: Vasilios Papademetriou, Paul A. Sobotka, Adam Witkowski

September 24, 2018

Presentation TCT 2018

Hypertension 2018 Update: From Ambulatory Monitoring to Definitional Controversies and More

Presenter: Vasilios Papademetriou, Paul A. Sobotka, Michael A. Weber

September 24, 2018

Presentation TCT 2018

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Presenter: John A. Bittl, Bernard J. Gersh, Michael A. Weber

September 24, 2018

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

Presentation TCT 2018

Point to Consider in the Review of the RDN Related Devices: US Regulatory

Presenter: Kenneth J. Cavanaugh Jr, Takafumi Ueno, Hiren Mistry

September 22, 2018

Presentation TCT 2018

Japanese Perspective and Experience on RDN Studies

Presenter: Kenneth J. Cavanaugh Jr, Takafumi Ueno

September 22, 2018

Advertisement

Sensing Renal Nerve Activity Before, During, and After Denervation: SyMap

Sensing Renal Nerve Activity Before, During, and After Denervation: Autonomix

Predicting Responders vs Non-Responders How to Solve the Unmet Need?

Who are the Ideal Candidates for Renal Denervation?

Clinical Trials All Look Positive: Is Renal Denervation Ready for Clinical Practice Now?

Alcohol-Mediated Renal Denervation Current Status and US Pivotal Trial Plans

Results and Update From the Vessix RE-INFORCE Program

Results and Update From the Paradise Hypertension Program (OFF-MED and ON-MED Studies)

Results and Update From the SPYRAL Hypertension Program (OFF-MED and ON-MED Trials)

Device Therapy Offers a Viable Alternative to Medical Therapy, and Should Be Considered as a Reasonable Alternative!

Drugs Work and Should Always Be Used as First-Line Therapy!

Potential Interventions for Hypertensive Patients With HFpEF

Uncontrolled Hypertension or Non-Compliant Patient? Assessment, Scope of the Problem, and Implications

Have the New U.S. Hypertension Guidelines and Treatment Targets Meaningfully Changed Care Pathways and Practice?

2018 European Guidelines and Perspectives on Hypertension

Hypertension 2018 Update: From Ambulatory Monitoring to Definitional Controversies and More

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Point to Consider in the Review of the RDN Related Devices: US Regulatory

Japanese Perspective and Experience on RDN Studies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content